CVD and PCSK9 Inhibitors: Analyzing the Outcome Studies and Understanding Their Implications

You are not currently logged in. If you are an NLA Member, you can save time by logging in before visiting this activity.

Click here to take this activity as a Non-Member

No votes yet
Accreditation Information

Content Domain
This activity falls under the following content domain(s):

  • Processing by PCSK9
  • 7.1.1 Clinical Trial Evidence

Learning Objectives
This activity teaches to the following learning objective(s):

  1. 5. Review the clinical trials of lipid-altering drug therapies used in cardiovascular disease prevention

Copyright © 2018 National Lipid Association. All Rights Reserved.

Privacy Policy Terms of Service